Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial

BMC Complementary and Alternative Medicine

Volumn 10, Issue , 2010, Pages

  Mandel, David R ^a   Eichas, Katy ^b   Holmes, Judith ^a  

^a NEC USA Inc   (United States)

^b Danisco USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIRHEUMATIC AGENT; ASCORBIC ACID; C REACTIVE PROTEIN; DIMETHYL SULFONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GANEDENBC; GBI 306086; GREEN TEA EXTRACT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBIOTIC AGENT; RETINOL; SELENIUM; UNCLASSIFIED DRUG; VITAMIN B GROUP; VITAMIN D; BIOLOGICAL PRODUCT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BACILLUS COAGULANS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; TREATMENT DURATION; BACILLUS; DAILY LIFE ACTIVITY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PAIN; PILOT STUDY; QUESTIONNAIRE; WALKING;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACILLUS; BIOLOGICAL PRODUCTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PILOT PROJECTS; PROBIOTICS; QUESTIONNAIRES; WALKING;

EID: 77249142976     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-10-1     Document Type: Article

References (28)

1. Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol 2008, 606:423-454. full_text, 18183940.
2. Goldin BR, Gorback SL. Clinical indications for probiotics: an overview. Clin Infect Dis 2008, 46(suppl 2):S96-S100. 10.1086/523333, 18181732.
3. Baharav E, Mor F, Halpern M, Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr 2004, 134:1964-1969.
4. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, Kiely B, Collins JK, Shanahan F. Is the mucosal route of administration esential for probiotic function? Subcutaneous administration is associated wtih attenuation of murine colitis and arthritis. Gut 2004, 53:694-700. 10.1136/gut.2003.027789, 1774028, 15082588.
5. Hatakka K, Martio J, Korpela M, Herranen M, Poussa T, Laasanen T, Saxelin M, Vapaatalo H, Moilanen E, Korpela R. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study. Scand J Rheumatol 2003, 32:211-215. 10.1080/03009740310003695, 14626627.
6. Schultz M, Linde HJ, Lehn N, Zimmerman K, Grossmann J, Falk W, Shölmerich J. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res 2003, 70:165-173. 10.1017/S0022029903006034, 12800870.
7. Vaarala O. Immunlogical effects of probiotics with speical reference to lactobacilli. Clin Exp Allergy 2003, 33:1634-1640. 10.1111/j.1365-2222.2003.01835.x, 14656348.
8. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in health subject following dietary consumption of the lactic acide bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr 2001, 20(2 suppl):149-156.
9. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh K, Liang MH, Dremers HM, Mayes MD, Merkel PA, Pillemer SR, Rveille JD, Stone JH, . for the National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008, 58:15-25. 10.1002/art.23177, 18163481, for the National Arthritis Data Workgroup.
10. Sesin CA, Bingham CO. Remission in rheumatoid arthritis: wishful thinking for clinical reality?. Semin Arthritis Rheum 2005, 35:185-196. 10.1016/j.semarthrit.2005.06.003, 16325659.
11. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473-488. 10.1038/nrd1109, 12776222.
12. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res 2001, 45:101-106.
13. Sartor RB. Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 1997, 11(suppl 3):17-22.
14. Malin M, Verronen P, Korhonen H, Syväoja EL, Salminen S, Mykkänen H, Arvilommi H, Eerola E, Isolauri E. Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: Evaluation of effect on gut defence mechanisms. Inflammopharmacology 1997, 5:219-236. 10.1007/s10787-997-0001-1, 17638132.
15. So JS, Kwon HK, Lee CG, Yi HJ, Park JA, Lim SY, Hwang KC, Jeon YH, Im SH. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol 2008, 45:690-699. 10.1016/j.molimm.2007.07.006, 17706783.
16. Rodriguez-Cabezas ME, Fisac F, Bailon E, Comalada M, Camuesco D, Xaus J, Concha A, Talavera P, Nieto A, Zarzuelo A, Galvez J. Lactobacillus fermentum exerts a beneficial effect in an experimental model of rheumatoid arthritis in mice. Proc Nutr Soc 2008, 67:E66.
17. Kano H, Kaneko T, Kaminogawa S. Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice. J Food Prot 2002, 65:153-160.
18. Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci 1998, 63:635-644. 10.1016/S0024-3205(98)00315-4, 9718093.
19. Broek MF, van Bruggen MC, Kiipman JP, Hazenberg MP, Berg WB. Gut flora induces and maintains resistance against streptococcal cell wall-induced arthritis in F344 rates. Clin Exp Immunol 1992, 88:313-317. 1554307, 1572097.
20. Casula G, Cutting SM. Bacillus probiotics: spore germination in the gastrointestinal tract. Appl Environ Microbiol 2002, 68:2344-2352. 10.1128/AEM.68.5.2344-2352.2002, 127533, 11976107.
21. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735. 10.1002/art.1780380602, 7779114.
22. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005, 23:S14-S18.
23. Tlaskalová-Hogenová H, Štěpánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Žádnthomampersand R, Kozáková H, Rossmann P, Bárová J, Sokol D, Funda DP, Borovská D, Řeháková Z, Šinkora J, Hofman J, Drastich P, Kokešová A. Commendal bacterial (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004, 93:97-108. 10.1016/j.imlet.2004.02.005, 15158604.
24. De Vecchi E, Drag L. Lactobacillus sporogenes or Bacillus coagulans: misidentification or mislabeling?. Int J Probiotics Prebiotics 2006, 1:3-10.
25. Tuomola E, Crittenden R, Playne M, Isolauri E, Salminen S. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 2001, 73(suppl):393S-398S.
26. Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol 2006, 17:204-210.
27. Hyronimus B, Le Marrec C, Sassi AH, Deschamps A. Acid and bile tolerance of spore-forming lactic acid bacteria. Int J Food Microbiol 2000, 61:193-197. 10.1016/S0168-1605(00)00366-4, 11078170.
28. Hyronimus B, Le Marrec C, Urdaci MC. Coagulin, a bacteriocin-like inhibitory substance produced by Bacillus coagulans I4. J Appl Microbiol 1998, 85:42-50. 10.1046/j.1365-2672.1998.00466.x, 9721655.